Clinical Trials Logo

Head and Neck Cancers clinical trials

View clinical trials related to Head and Neck Cancers.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02748707 Active, not recruiting - Clinical trials for Oral Squamous Cell Carcinoma

Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study

ERLO-XIB
Start date: August 18, 2015
Phase: Phase 2
Study type: Interventional

This is a phase II randomized clinical trial to study the effect of COX-2 inhibitor Celecoxib and EGFR tyrosine kinase inhibitor Erlotinib alone or in combination on molecular markers of apoptosis and angiogenesis.

NCT ID: NCT00580203 Active, not recruiting - Clinical trials for Head and Neck Cancers

Collection Of Tissue, Blood, and Other Specimens From Patients With Head and Neck Tumors To Study the Causes, Diagnosis, Prevention and Treatment of Cancers

Start date: February 2004
Phase:
Study type: Observational

This is a protocol to collect tissues, blood, and other specimens from patients with malignant or nonmalignant diseases of the head and neck. Collected specimens will be used in laboratory studies to investigate the growth, development, and transformation of normal and abnormal cells in the future.

NCT ID: NCT00490061 Active, not recruiting - Clinical trials for Head and Neck Cancer

Phase II Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy

Start date: July 2007
Phase: Phase 2
Study type: Interventional

We propose to combine lapatinib with RT alone in patients with locally advanced head and neck cancer who cannot tolerate chemotherapy. The main objective of the study is to determine the efficacy of combining concurrent radiation and lapatinib in terms of time-to-progression (TTP) in this group of patients. In addition, we will determine the 2-year locoregional control rate (LRC), progression-free survival (PFS) and overall survival (OS) in these patients. We will also evaluate the profile and frequency of late toxicity, specifically mucosal and dermatologic toxicity, of the combination of lapatinib and RT in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).